Cardiovascular and Interventional Radiological Society of Europe Commentary on the Treatment of Chronic Cerebrospinal Venous Insufficiency by Reekers, J.A. et al.
CIRSE COMMENTARY
Cardiovascular and Interventional Radiological Society of Europe
Commentary on the Treatment of Chronic Cerebrospinal Venous
Insufficiency
J. A. Reekers • M. J. Lee • A. M. Belli •
F. Barkhof
Received: 1 November 2010 / Accepted: 3 November 2010 / Published online: 7 December 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Chronic cerebrospinal venous insufficiency
(CCSVI) is a putative new theory that has been suggested
by some to have a direct causative relation with the
symptomatology associated with multiple sclerosis (MS)
[1]. The core foundation of this theory is that there is
abnormal venous drainage from the brain due to outflow
obstruction in the draining jugular vein and/or azygos
veins. This abnormal venous drainage, which is charac-
terised by special ultrasound criteria, called the ‘‘venous
hemodynamic insufficiency severity score’’ (VHISS), is
said to cause intracerebral flow disturbance or outflow
problems that lead to periventricular deposits [2]. In the
CCSVI theory, these deposits have a great similarity to the
iron deposits seen around the veins in the legs in patients
with chronic deep vein thrombosis. Zamboni, who first
described this new theory, has promoted balloon dilatation
to treat the outflow problems, thereby curing CCSVI and
by the same token alleviating MS complaints. However,
this theory does not fit into the existing bulk of scientific
data concerning the pathophysiology of MS. In contrast,
there is increasing worldwide acceptance of CCSVI and the
associated balloon dilatation treatment, even though there
is no supporting scientific evidence. Furthermore, most of
the information we have comes from one source only. The
treatment is called ‘‘liberation treatment,’’ and the results
of the treatment can be watched on YouTube. There are
well-documented testimonies by MS patients who have
gained improvement in their personal quality of life (QOL)
after treatment. However, there are no data available from
patients who underwent unsuccessful treatments with
which to obtain a more balanced view. The current forum
for the reporting of success in treating CCSVI and thus MS
seems to be the Internet. At the CIRCE office and the MS
Centre in Amsterdam, we receive approximately 10 to 20
inquiries a month about this treatment. In addition, many
interventional radiologists, who are directly approached by
MS patients, contact the Cardiovascular and Interventional
Radiological Society of Europe (CIRSE) for advice.
Worldwide, several centres are actively promoting and
performing balloon dilatation, with or without stenting, for
CCSVI. Thus far, no trial data are available, and there is
currently no randomized controlled trial (RCT) in progress
Therefore, the basis for this new treatment rests on anec-
dotal evidence and successful testimonies by patients on
the Internet. CIRSE believes that this is not a sound basis
on which to offer a new treatment, which could have
possible procedure-related complications, to an often des-
perate patient population.
Introduction
CIRSE believes that the CCSVI theory in its current form
has a number of inconsistencies. The core of this new
theory is the CCSVI syndrome, i.e., abnormal venous
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drainage from the brain. However, venous drainage from
the head has an impressive anatomic variation, which has
not been well catalogued in most textbooks. In addition,
valves can be present at a variety of sites in the head and
neck veins. Indeed, interventional radiologists who practise
parathyroid sampling know about this huge variety in
venous anatomy. In addition to the huge variation in nor-
mal venous anatomy, the jugular veins have some natural
narrowing at two sites, and the azygos vein, so prominent
in CCSVI theory, does not drain the brain at all. The
azygous vein obviously can drain the spinal cord, but not
solely, because many intercostal venous collateral veins
fulfil the same function.
In addition, the fact that this imaging is performed with
the patient in the supine position has a great influence on
blood flow and image interpretation. There recently have
been randomised studies comparing so-called ‘‘venous
stenoses’’ in patients with and without MS [3, 4]. Both
studies showed that there was no difference in the preva-
lence of venous stenoses between the two groups. This
seems to be a strong argument against the existence of
CCSVI. However, those physicians performing CCSVI
treatment point out that these studies were not performed
according to the VHISS criteria. The other part of the theory
is that the venous outflow obstruction must be treated.
However, if there is a real haemodynamic venous outflow
obstruction, there should also be a pressure gradient, and
this gradient should disappear after successful balloon
dilatation. It has been shown, and confirmed by those who
perform balloon dilatation for CCSVI, that over the
so-called ‘‘stenosis’’ there is never a measurable pressure
gradient. Again, those who perform this treatment will say
that it is not the pressure gradient but the change in outflow
pattern caused by this stenosis that is the pathologic entity.
What remains is the issue of anecdotal successful treat-
ments. Undoubtedly, some patients obtain symptom relief
after treatment for CCSVI, but this could easily be just a
placebo effect. Many treatment successes in medicine are
based on or helped by a placebo effect. In itself, there is
nothing wrong with the placebo effect as long as we recog-
nize that this is at play. It is also known that the more invasive
the treatment and the more the treating physician believes in
the treatment, the stronger the placebo effect is. Furthermore,
MS can affect emotional and labile responses and is char-
acterized by spontaneous relapses and remissions. This
makes the gathering of scientific evidence to support CCSVI
theory difficult in anything other than an RCT.
What we now have is the dilemma of a new treatment
being promoted and performed by some early pioneers,
with the popular press trumpeting its success and thus
decreasing the chances of performing a properly conducted
trial because it is considered unethical not to offer patients
this new and promising treatment. The primary task of
physicians is primum non nocere or not doing harm. We
believe that harm can be caused by offering treatments
without any scientific proof of efficacy as well as the more
usual forms of medical harm. Pseudo-arguments such as
‘‘There is nothing else’’ or ‘‘Do you know how much they
pay for medication that does not work?’’ are not valid and
scientific arguments.
Confronted with these contradictions and lack of evidence
for CCSVI treatment, some pioneers have taken to calling
their work on MS patients a ‘‘phase 1 study.’’ However, a
phase 1 study without a protocol, that has not been approved
by a medical ethical committee, that does not require
informed consent, and that does not have safety committee
oversight does not qualify! CIRSE believes that only prop-
erly conducted trials with significant scientific rigor can
solve this dilemma. We at CIRCE believe that a small pro-
spective randomised trial, with a sham arm, is required. A
trial monitored by an independent society, such as CIRSE
and/or the European Society of Neurology, would be ideal.
As doctors and interventional radiologists, we certainly
hope that all of the anecdotal reports detailing improve-
ments in QOL will prove to be true and that patients will
benefit from this new treatment. Interventional radiologists
have a long history of introducing pioneering treatments
during the last 30 years that have proven to be of enormous
benefit to patients. Recently new treatments, such as fibroid
embolization, vertebroplasty, and carotid stenting, have all
been interrogated by randomized trials. We believe that
CCSVI treatment should be evaluated in the same manner.
Furthermore, we believe that until real scientific data are
available for CCSVI and balloon dilatation, this treatment
should not be offered to MS patients outside of a well-
designed clinical trial.
Open Access This article is distributed under the terms of the
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